In Silico Comparative Evaluation of Biotechnology-Based Engineered Bacterial Therapeutic Platforms for Targeted Sensing, Controlled Payload Delivery, and Biocontainment

• Raghda Saad Jameel

  Department of Pathological Analysis , College of Science, Wasit University

General Background Engineered bacterial therapeutics have emerged as programmable living systems capable of site-specific sensing and controlled therapeutic delivery. Specific Background Despite rapid advances in synthetic biology, there remains difficulty in selecting optimal platform architectures due to the lack of structured comparative evaluation tools. Knowledge Gap Existing literature lacks a decision-oriented framework that systematically compares engineered bacterial therapeutic platforms across integrated engineering and translational criteria. Aims This study aims to develop an in silico comparative evaluation model to assess representative therapeutic platforms based on specificity, payload control, biosafety, manufacturability, and translational readiness. Results The analysis identifies dual-input logic-gated biocontainment-enabled systems as the highest-ranked platform, followed by biomarker-responsive circuits, while constitutive and tumor-colonizing systems show lower balanced performance. Novelty The study introduces a weighted multi-criteria scoring framework that transforms descriptive knowledge into a structured decision-making tool for platform selection. Implications The proposed model provides a systematic basis for guiding design prioritization, optimization strategies, and future experimental validation in engineered bacterial therapeutics.

Keywords: Engineered Bacterial Therapeutics, Synthetic Biology, In Silico Evaluation, Gene Circuits, Biocontainment

1. Dual-input architectures achieve highest balance across evaluation criteria
2. Biomarker-responsive systems provide strong contextual activation with moderate complexity
3. Simpler and tumor-targeting designs show limitations in safety and control balance

K. Kim, M. Kang, and B. K. Cho, “Systems and Synthetic Biology-Driven Engineering of Live Bacterial Therapeutics,” Frontiers in Bioengineering and Biotechnology, vol. 11, 2023, Art. no. 1267378.

A. N. Nazir, F. H. N. Hussain, and A. Raza, “Advancing Microbiota Therapeutics: The Role of Synthetic Biology in Engineering Microbial Communities for Precision Medicine,” Frontiers in Bioengineering and Biotechnology, vol. 13, 2025, Art. no. 1599294.

I. Zalila-Kolsi, “Engineered Bacteria as Living Therapeutics: Next-Generation Precision Tools for Health, Industry, Environment, and Agriculture,” AIMS Microbiology, vol. 11, no. 4, pp. 946–962, 2025.

C. Dudeja et al., “Microbial Genome Editing with CRISPR-Cas9: Recent Advances and Emerging Applications Across Sectors,” Fermentation, vol. 11, no. 7, 2025, Art. no. 410.

X. Wang et al., “Bacterial Synthetic Biology: Tools for Novel Drug Discovery,” Expert Opinion on Drug Discovery, vol. 18, no. 11, pp. 1267–1284, 2023.

S. Dey, C. E. Seyfert, C. Fink-Straube, et al., “Thermo-Amplifier Circuit in Probiotic Escherichia coli for Stringently Temperature-Controlled Release of a Novel Antibiotic,” Journal of Biological Engineering, vol. 18, 2024, Art. no. 33.

Z. Gao et al., “Application Progress and Biosafety Challenges of Gene Editing and Synthetic Biotechnology in Diagnosis, Treatment and Prevention of Infectious Diseases,” Biosafety and Health, vol. 7, no. 4, pp. 245–259, 2025.

M. Jayaprakash et al., “Bacteria-Mediated Cancer Therapy: Therapeutic Insights into Human Microbiota and Engineered Bacteria in Cancer,” Biomedicine and Pharmacotherapy, vol. 188, 2025, Art. no. 118370.

K. Song et al., “Innovations from Design to Applications in Synthetic Biology,” Biosensors, vol. 15, 2025, Art. no. 221.

Y. Wu, M. Zhou, Y. Wan, et al., “The Microbial Conductor of Cancer Hallmarks: Intratumoral Microbiome as a Multidimensional Oncogenic Modulator,” Frontiers in Microbiology, vol. 16, 2026, Art. no. 1695187.

S. Dey and S. Sankaran, “Engineered Bacterial Therapeutics with Material Solutions,” Trends in Biotechnology, vol. 42, no. 12, pp. 1663–1676, 2024.

J. Nam, Y. Lee, S. Lee, H. Choi, S. Y. Lee, and D. Yang, “Synthetic Biology Strategies for Engineering Probiotics and Commensal Bacteria for Diagnostics and Therapeutics,” Biotechnology Advances, vol. 87, 2026, Art. no. 108782.

A. Armstrong and M. Isalan, “Engineering Bacterial Theranostics: From Logic Gates to In Vivo Applications,” Frontiers in Bioengineering and Biotechnology, vol. 12, 2024, Art. no. 1437301.

J. Hahn, S. Ding, J. Im, T. Harimoto, K. W. Leong, and T. Danino, “Bacterial Therapies at the Interface of Synthetic Biology and Nanomedicine,” Nature Reviews Bioengineering, vol. 2, no. 2, pp. 120–135, 2024.

J. Lee, S. McClure, R. R. Weichselbaum, and M. Mimee, “Designing Live Bacterial Therapeutics for Cancer,” Advanced Drug Delivery Reviews, vol. 221, 2025, Art. no. 115579.

N. Siguenza et al., “Engineered Bacterial Therapeutics for Detecting and Treating CRC,” Trends in Cancer, vol. 10, no. 7, pp. 588–597, 2024.

R. Srivastava and C. F. Lesser, “Living Engineered Bacterial Therapeutics: Emerging Affordable Precision Interventions,” Microbial Biotechnology, vol. 17, no. 6, 2024, Art. no. e70057.

K. Jin, Y. Huang, H. Che, and Y. Wu, “Engineered Bacteria for Disease Diagnosis and Treatment Using Synthetic Biology,” Microbial Biotechnology, vol. 18, no. 1, 2025, Art. no. e70080.